Precigen, Inc.
IN VIVO CONTROLLED COMBINATION THERAPY FOR TREATMENT OF CANCER
Last updated:
Abstract:
Disclosed herein are improved methods for treatment of brain cancer (such as glioma/glioblastoma) via ligand-inducible gene-switch controlled in vivo expression of an immunomodulator (i.e., IL-12) in combination with one or more other immunomodulators (i.e., an immune cell check point inhibitor; e.g., such as a PD-1 inhibitor or a PD-1 binder.
Status:
Application
Type:
Utility
Filling date:
27 Jun 2019
Issue date:
23 Dec 2021